Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
Investing.com - H.C. Wainwright raised its price target on Palvella Therapeutics (NASDAQ:PVLA) to $75.00 from $38.00 on Monday, while maintaining a Buy rating on the stock. The stock, which has surged nearly 300% year-to-date and currently trades near its 52-week high of $47.97, appears overvalued according to InvestingPro Fair Value metrics.
The price target increase comes as the company approaches the expected readout in the first quarter of 2026 from the Phase 3 SELVA trial of QTORIN Rapamycin in patients with microcystic Lymphatic Malformation (mLM).
H.C. Wainwright noted that focus is shifting toward the regulatory and potential commercial pathway for the treatment, emphasizing the importance of early engagement with payers regarding the rarity and severity of the disease.
The firm also highlighted the significance of educating physicians about the benefits of QTORIN Rapamycin to encourage early adoption of the treatment.
As part of its commercial launch preparations, Palvella has hired Ashley Kline, described as a rare disease commercial veteran with experience successfully launching a first-in-disease topical therapy in an indication that previously had no FDA-approved therapies.
In other recent news, Palvella Therapeutics reported its Q2 2025 earnings, revealing a strong cash position but also high operating expenses. The company provided future earnings per share (EPS) forecasts that suggest continued financial losses. These developments have garnered attention from investors and analysts alike. While the stock experienced a notable decline following the earnings call, the focus remains on the company’s financial health and strategic plans moving forward. The earnings report and forecasts are critical for stakeholders assessing the company’s trajectory. Investors are keenly observing how Palvella Therapeutics will manage its expenses and leverage its cash reserves. Analyst opinions and evaluations may follow, potentially impacting investor sentiment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.